Stay updated with breaking news from Administration Measures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This is a review of China's key developments during H2 2022 in antitrust, civil law, corporate, data and cybersecurity, foreign investment and medical treatment including China’s Supreme Court proposed revisions to civil litigation rules under the Anti Monopoly Law.
This article covers regulatory updates made between August and December 2022 in China, Hong Kong S.A.R., South Korea, Thailand and the Phillipines. Many focus on increased ingredient restrictions; most notably a ban on CBD products in Hong Kong S.A.R.
This article covers regulatory updates made between August and December 2022 in China, Hong Kong S.A.R., South Korea, Thailand and the Phillipines. Many focus on increased ingredient restrictions; most notably a ban on CBD products in Hong Kong S.A.R.
Investors are eyeing opportunities in China. One of the sectors of interest is the biotech sector.
A prime opportunity for China’s domestic drug development industry to capitalise on the growing need for new therapeutics.